Skip to main content
OpenTrials
Completed

NCT Number: NCT04330508

Effects of Direct-acting Antiviral Agents on HCV Cognitive Function, and Depression in HCV Related Cirrhosis: A Prospective Clinical Trial

Minimal hepatic encephalopathy (MHE) is an important clinical variant of hepatic encephalopathy (HE), which occurs in up to 60-70% of patients with cirrhosis. The condition comprises a cognitive impairment, observed in patients with cirrhosis who have no clinical evidence of overt hepatic encephalopathy (OHE). It is associated with an increased incidence of road traffic accidents, reduced quality of life and it affects the ability to perform tasks of daily living. Successful treatment of hepatitis C has been reported to be associated with 62-84% reduction in all-cause mortality (deaths), 68-79% reduction in risk of HCC and 90% reduction in risk of liver transplantation. In addition, studies have shown that viral eradication may improve cognition when given interferon based regimens for HCV. With the available of safe, efficacious, all oral regimens for HCV, we plan to prospectively analyse the change in mood, depression and cognitive function in response to DAA therapy, in relation to outcomes of treatment.

Completed

Looking for future studies?

Notify Me

Key information

About this study

Investigations will be performed according to the Declaration of Helsinki and approval of the enrolment as well as the usage of patient blood samples for research purpose will be obtained from the institutional ethics committee, and written informed consent will be obtained from all patients.The primary analysis upon which the sample size consideration was based involved the comparison of the SVR subgroup and the subgroup of patients without SVR. For the sample size calculation, we a two-factorial design (time course × SVR) with the use of a two-way analysis of variance (ANOVA) analysis, a significance level of 5% and a statistical power of at least 80% to detect a medium effect size (d = 0.5) and thus to show a significant group difference. Based on this background, the optimal sample size is calculated to be a total of 102 subjects. To consider asymmetric subgroups and to allow for a moderate dropout rate and additional calculations (secondary study objectives), we aim to include a total of at least 150 study participants in each group with 25 healthy volunteers as controls.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18-65 years and chronic HCV infection.
  • Group A: Patients with hepatitis C (Non-cirrhotic) [n= 150]
  • Group B: Patients with hepatitis C related compensated-cirrhosis [n= 150]
  • Group C: Healthy volunteers [n= 25]

Exclusion criteria

  • Current overt hepatic encephalopathy or during the last 1 month
  • TIPS (transjugular intra- hepatic porto-systemic shunt)
  • elective surgery planned within the next 8 weeks
  • unable to give informed consent
  • HIV infection
  • chronic respiratory insufficiency
  • current infection and receiving antibiotics
  • renal failure (serum creatinine ≥ 1.5 mg/l)
  • hepatocellular carcinoma,
  • patient with other neurological disease
  • intake of sedatives, antidepressants, benzodiazepines, or benzodiazepines-antagonists (flumazenil, neuromuscular blocking agents)

Treatment and study plan

Depression and Cognitive Tests

Other

Health Related Quality of Life, neurocognitive tests, PHES

Other names: SF36

Primary outcomes

  1. Cognitive performance

    Time frame: Day 0

    Computerized battery (Reaction times, simple and choice, visual memory, Number connection test, and Inhibitory Control Test)

  2. Cognitive performance

    Time frame: 90 days after treatment completion

    Computerized battery (Reaction times, simple and choice, visual memory, Number connection test, and Inhibitory Control Test)

  3. Cognitive performance using conventional tests

    Time frame: Day 0

    Psychometric hepatic encephalopathy score (PHES), Indian Version.

  4. Cognitive performance using conventional tests

    Time frame: 90 days after treatment completion

    Psychometric hepatic encephalopathy score (PHES), Indian Version.

  5. HRQOL by SF-36

    Time frame: Day 0

  6. HRQOL by SF-36

    Time frame: 90 days after treatment completion

Secondary outcomes

  1. Depression Scale

    Time frame: Day 0

    Beck's Depression Inventory (BDI) Generalized anxiety disorder (GAD 7 score) Psychometric hepatic encephalopathy Score (PHES) Montreal Cognitive assessment Score (MoCA Score)

  2. Depression Scale

    Time frame: 90 days after treatment completion

    Beck's Depression Inventory (BDI) Generalized anxiety disorder (GAD 7 score) Psychometric hepatic encephalopathy Score (PHES) Montreal Cognitive assessment Score (MoCA Score)

Sponsors and collaborators

Lead sponsor

Post Graduate Institute of Medical Education and Research, Chandigarh

Other

Registry information

Official study title

Effects of Direct-acting Antiviral Agents on Cognitive Function, and Depression in Chronic Hepatitis C

Important dates

Study start
2018
Primary completion
2021
Study completion
2021
First posted
Apr 1, 2020
Registry last updated
Feb 13, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.